Literature DB >> 22182950

Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation.

S Ruf1, K Behnke-Hall, B Gruhn, J Bauer, M Horn, J Beck, A Reiter, H J Wagner.   

Abstract

BACKGROUND: Epstein-Barr Virus (EBV) a gamma-herpes virus is associated with a spectrum of lymphoid and epithelial malignancies including posttransplant lymphoproliferative disorders (PTLD). EBV-load measurement has been shown to be important for the monitoring of these patients. However, in contrast to the viral quantification of human immunodeficiency virus or human hepatitis C virus, the EBV-load measurement has not been completely standardized as yet.
OBJECTIVES: In this study, we compared the EBV DNA levels in whole blood (WB), plasma, peripheral mononuclear cells (PBMC) and B-cells (BC) in children and adolescents after heart transplantations (HTx) and allogeneic hematopoietic stem cell transplantations (HSCT). STUDY
DESIGN: In a period of 2 years (from May 2007 to May 2009) we collected 547 samples of 96 cardiac transplant recipients and 248 samples of 37 patients who underwent HSCT. For EBV DNA quantification we used a duplex real-time PCR (ABI Prism 7500, Applied Biosystems). Additionally, EBV-load of PBMC and BC were normalized with respect to endogenous cell DNA.
RESULTS: In both patient populations we found no significant difference of test sensitivity for the EBV detection. In PBMC as well as BC, there was a high correlation between the analysis of cells with and without normalization in both populations. Spearman's correlation coefficient ρ between PBMC without and PBMC with normalization was ρ=0.98 (P<0.0001) in patients after HTx and ρ=0.99 (P<0.0001) in patients after HSCT. Correlation between BC with and without normalization was ρ=0.98 (P<0.0001) in patients after HTx and ρ=0.995 (P<0.0001) in patients after HSCT. When comparing the different blood compartments for EBV quantification in both populations, the strongest correlations were found between the EBV DNA levels in WB and PBMC (HTx: ρ=0.93, P<0.0001; HSCT: ρ=0.81, P<0.0001) followed by PBMC and BC (HTx: ρ=0.87, P<0.0001; HSCT: ρ=0.81, P<0.0001) as well as WB and BC (HTx: ρ=0.86, P<0.0001; HSCT: ρ=0.75, P<0.0001). In contrast, the correlation coefficients between plasma and the other blood compartments (WB as well as PBMC or BC) were lower. Six patients developed seven episodes of PTLD (five patients after HTx and one after renal transplantation). Analyzing the different blood compartments, we found that a threshold of WB ≥20,000EBV-copies/ml and plasma ≥1000EBV-copies/ml had the highest sensitivities and specificities (WB: sensitivity 100%, specificity 87% and plasma: sensitivity 88%, specificity 98%).
CONCLUSION: Normalization towards an endogenous control does not seem to be necessary for EBV quantification in peripheral blood. The analysis of whole blood correlates well with B-cells and PBMC. Routine screening of EBV DNA in whole blood appeared to be a useful tool supplemented by EBV-load measurement in plasma to discriminate chronic high EBV-load carrier without risk for PTLD from those who are at risk for PTLD. Values in whole blood higher than 20,000EBV-copies/ml WB and plasma values higher than 1000EBV-copies/ml plasma indicated PTLD in our series. Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22182950     DOI: 10.1016/j.jcv.2011.11.010

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  12 in total

Review 1.  Standardization of Nucleic Acid Tests for Clinical Measurements of Bacteria and Viruses.

Authors:  Jernej Pavšič; Alison S Devonshire; Helen Parkes; Heinz Schimmel; Carole A Foy; Maria Karczmarczyk; Ion Gutiérrez-Aguirre; Isobella Honeyborne; Jim F Huggett; Timothy D McHugh; Mojca Milavec; Heinz Zeichhardt; Jana Žel
Journal:  J Clin Microbiol       Date:  2014-11-12       Impact factor: 5.948

2.  Enterovirus RNA in longitudinal blood samples and risk of islet autoimmunity in children with a high genetic risk of type 1 diabetes: the MIDIA study.

Authors:  Ondrej Cinek; Lars C Stene; Lenka Kramna; German Tapia; Sami Oikarinen; Elisabet Witsø; Trond Rasmussen; Peter A Torjesen; Heikki Hyöty; Kjersti S Rønningen
Journal:  Diabetologia       Date:  2014-07-23       Impact factor: 10.122

3.  Cognate HLA absence in trans diminishes human NK cell education.

Authors:  Vanessa Landtwing; Ana Raykova; Gaetana Pezzino; Vivien Béziat; Emanuela Marcenaro; Claudine Graf; Alessandro Moretta; Riccarda Capaul; Andrea Zbinden; Guido Ferlazzo; Karl-Johan Malmberg; Obinna Chijioke; Christian Münz
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

4.  The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases.

Authors:  Jennifer A Kanakry; Aparna M Hegde; Christine M Durand; Allan B Massie; Amy E Greer; Richard F Ambinder; Alexandra Valsamakis
Journal:  Blood       Date:  2016-01-07       Impact factor: 22.113

Review 5.  Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines.

Authors:  Jan Styczynski; Walter van der Velden; Christopher P Fox; Dan Engelhard; Rafael de la Camara; Catherine Cordonnier; Per Ljungman
Journal:  Haematologica       Date:  2016-07       Impact factor: 9.941

Review 6.  Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities.

Authors:  Rama Al Hamed; Abdul Hamid Bazarbachi; Mohamad Mohty
Journal:  Bone Marrow Transplant       Date:  2019-05-14       Impact factor: 5.483

7.  Performance of the Real-Q EBV Quantification Kit for Epstein-Barr Virus DNA Quantification in Whole Blood.

Authors:  Hee Jae Huh; Jong Eun Park; Ji Youn Kim; Sun Ae Yun; Myoung Keun Lee; Nam Yong Lee; Jong Won Kim; Chang Seok Ki
Journal:  Ann Lab Med       Date:  2017-03       Impact factor: 3.464

8.  Lytic EBV infection investigated by detection of Soluble Epstein-Barr virus ZEBRA in the serum of patients with PTLD.

Authors:  Mohammed Habib; Marlyse Buisson; Julien Lupo; Felix Agbalika; Gérard Socié; Raphaele Germi; Monique Baccard; Berthe-Marie Imbert-Marcille; Jacques Dantal; Patrice Morand; Emmanuel Drouet
Journal:  Sci Rep       Date:  2017-09-05       Impact factor: 4.379

9.  Long term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with rheumatoid arthritis - A three years retrospective study.

Authors:  Nathalie Balandraud; Gaetan Texier; Emmanuel Massy; Olivier Muis-Pistor; Marielle Martin; Isabelle Auger; Marie-Caroline Guzian; Sandrine Guis; Thao Pham; Jean Roudier
Journal:  PLoS One       Date:  2017-02-15       Impact factor: 3.240

10.  Automated quantification of Epstein-Barr virus in whole blood for post-transplant lymphoproliferative disorders monitoring.

Authors:  Maud Salmona; Karl Stefic; Nadia Mahjoub; Flore Sicre de Fontbrune; Sarah Maylin; François Simon; Catherine Scieux; Gérard Socié; Marie-Christine Mazeron; Jérôme LeGoff
Journal:  Virol J       Date:  2020-02-03       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.